In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Atlassian’s current price exceeds its PERT-weighted fair value by 36%, indicating potential overvaluation amid weak financial health (overall score 1/5) and a high downside risk of 100% in Monte Carlo scenarios. Valuation metrics, especially DCF and EV/EBITDA, show significant downside versus analyst targets. Elevated volatility and poor profitability raise investment risk.